Sonnet BioTherapeutics Holdings, Inc. (SONN): חוב להון עצמי

Sonnet BioTherapeutics develops innovative tumor-fighting methods utilizing the FHAB platform for targeted drug delivery. This chart of the share price on GURU.Markets shows that the total debt-to-equity ratio is 0.00. The high value of the product will provide the company with market influence, while the localization of development in the US completely eliminates geopolitical threats and trade barriers.

This metric is calculated as the ratio of total liabilities to net asset value, measuring the business's reliance on debt financing relative to its equity. Analyzing the D/E ratio (total debt-to-equity) allows for an assessment of the financial stability of Sonnet BioTherapeutics (SONN) as it implements a capital-intensive strategy to develop targeted cancer immunotherapy based on the FHAB platform.